Poster Downloads_Biocytogen Pharmaceuticals (Beijing) Co., Ltd._Biocytogen, drug development, antibody discovery

top

Please input keywords

EN

Management team

Social Responsibility

Antibody Assets

Project Integrum

Antibody discovery platforms

Clinical pipeline

Preclinical pipeline

Humanized animal models

KO mouse models

Immunodeficient mice/rats

Disease mouse models

Pharmacology Service

Therapeutic area

Types of services

By technologies

Animal Breeding

Animal Cryopreservation

Animal Rederivation

Microbial detection

Animal Breeding

Animal Cryopreservation

Animal Rederivation

Stock Information

Financial Reports

Listing Documents

Announcements & Notices

Corporate Governance

Investor Calendar

Poster Downloads

Media Center

Poster Downloads

Brochure

World ADC San Diego2022丨YH013, a fully-human EGFR x MET bispecific ADC exhibits outstanding specificity and anti-tumor efficacy

ASCO 2022: A phase I open-label dose escalation of YH003 (CD40 mAb) in combination with toripalimab (PD-1 mAb) in patients with advanced solid tumors

ASCO 2022: A first-in-human phase I dose escalation of YH001 (CTLA-4 mAb) in combination with PD-1 mAb in patients with advanced solid tumors

AACR 2022: Evaluating Delivery of TFR1-targeting Therapies to the CNS in a Novel Humanized TFR1 Mouse Model

AACR 2022: Developing a Translational Tool for GLP-1-Based Therapeutic Agonists in Humanized GLP1R Mice

AACR 2022: YH008, a PD-1-CD40 Bispecific Antibody, Inhibits Tumor Growth In Vivo Through PD-1-Dependent Activation of CD40 Signaling

AACR 2022: B-hIL12A/hIL12B/hIL12RB1/hIL12RB2: A Novel Animal Model for Generation of IL12 Therapies

AACR 2022: Evaluation of Therapeutic Drug Candidates Using a Novel Humanized B-hCSF1/hCSF1R

AACR 2022: Evaluating In Vivo Efficacy of Anti-VSIG4 Antibodies in Humanized B-hVSIG4 Mice

1 … 6 7 8 9 10 … 14